IMIPENEM CILASTATIN FOR THE TREATMENT OF MODERATELY SEVERE BACTERIAL-INFECTIONS

The broad spectrum and relative lack of significant side effects of imipenem/cilastatin have made this antibiotic the subject of worldwide study concerning its efficacy as monotherapy for bacterial infections. The authors conclude that imipenem/cilastatin should be used in mild and moderately severe infections as intravenous (IV) therapy for nosocomial infection; as IV therapy for community-acquired infections in hospitalized immunocompromised patients; intramuscularly for community-acquired infections and recurrent infections in the outpatient setting, if a multiresistant organism is isolated or suspected; and intramuscularly in soft tissue infections in IV drug addicts when peripheral venous access is difficult or impossible.